An ASNC Information Statement: Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis
Resource Type
Information Statements, Practice Points
Year Published
2022
Related Resources
Cases
PET Case: This is Why We Do Cardiac PET: Comparison of SPECT and PET in the Same Patient
Case summary: A 60-year-old patient with recurring exertional angina undergoes cardiac PET…
ASNC Joins Coalition Endorsing H.R. 8163, the Provider Reimbursement Stability Act
05-19-2026_AMA-coalition Letter on HR8163, Provider Reimbursement Stability Act
ASNC-Led Coalition Comments to Congress on MACRA Modernization
ASNC-CVsocieties_MACRA Modernization Letter on AUC_05-08-2026
